The Clinical Research E-News

Similar documents
The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

Jefferson Kimmel Cancer Center Network Presents: The Clinical Research E-News. January 14, 2009

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News

SKCN E-Newsletter Volume 9 ISSUE 9 Regional Network Office

The Clinical Research E-News

The Clinical Research E-News

The Clinical Research E-News Volume 8: ISSUE 7: July 29, 2016

SKCN E-Newsletter Volume 10 ISSUE 5 Regional Network Office

RTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman

National Cancer Institute Clinical Trial Cooperative Groups

Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT

THE TARGET. News from the Department of Radiation Oncology

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD

Research Strategy Committee Mitch Machtay, MD Deputy Group Chair, NRG RSC. NRG Semi-Annual Meeting Sunday, February 9, 2014

CancerPACT Cancer Patients Alliance for Clinical Trials

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List

Eligibility Form. 1. Patient Profile. (This form must be completed before the first dose is dispensed.) Request prior approval for enrolment

Clinical Trials OPEN to ENROLLMENT

Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer

THE TARGET. New radiation oncology facility showcases latest technology. News from the Department of Radiation Oncology.

National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:

Open clinical uro-oncology trials in Canada

SKCN E-Newsletter Volume 9 ISSUE 10 Regional Network Office

Open clinical uro-oncology trials in Canada

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December

Open clinical uro-oncology trials in Canada

The RPC s Evaluation of Advanced Technologies. AAPM Refresher Course July 29, 2008 Geoffrey S. Ibbott, Ph.D. and RPC Staff

Erbitux. Erbitux (cetuximab) Description

Open clinical uro-oncology trials in Canada

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer. Project Overview Ronald C. Chen, MD MPH

CancerPACT Cancer Patients Alliance for Clinical Trials

The Clinical Research E-News Volume 7: ISSUE 11: November 20, 2015

SHORE HEALTH SYSTEM INSTITUTIONAL REVIEW BOARD MHE Boardroom April 10, 2012

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List

WASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles

Update on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver

Avastin (bevacizumab) DRUG.00028, CG-DRUG-68

Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón

SUMMARY OF CHANGES Amendment 6, Version Date: March 29, 2010 [Broadcast: April 8, 2010]

CALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer

CancerPACT Cancer Patients Alliance for Clinical Trials

6/23/2010. Publicly Funded Clinical Trials in the Era of Comparative Effectiveness Research. Goals of Therapeutic Clinical Trials

THE TARGET. News from the Department of Radiation Oncology. UT Southwestern to extend advanced radiation therapy techniques statewide

Trial record 1 of 1 for: GO28341 Previous Study Return to List Next Study

Critical Clinical Updates

SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List

Roche setting the standards of cancer care Oncology Event for Investors, June 19

Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy

CLINICAL TRIALS ACC. Jul 2016

Page 1, column 2, entry for Lech Papiez: Line 2: Former was added in front of Medical Lines 4-7 of his entry were deleted.

Breast Cancer Clinical Trials in Georgia

Session II: Academic Research in Breast Cancer: Challenges and Opportunities Robert L. Comis, MD ECOG-ACRIN Group Co-Chair

EASTERN COOPERATIVE ONCOLOGY GROUP

What Can Go Wrong in Radiation Treatment: Data from the RPC. Geoffrey S. Ibbott, Ph.D. and RPC Staff

肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部

Clinical Trial Credentialing:

Cancer Registry Report. Cancer Focus: Melanoma

Arm A: Induction Gemcitabine 1000 mg/m 2 IV once a week for 6 weeks.

TRB 97th Annual Meeting

Our Clinical Trials. Oncology

Navigating Alliance Protocols

Combined modality treatment for N2 disease

National Cancer Policy Forum Workshop on Multi-Center Phase 3 Clinical Trials and NCI Cooperative Groups

Management of advanced non small cell lung cancer

Combined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago

MULTI-GROUP AUDITS, THE CENTRAL MONITORING PORTAL, AND OTHER CTSU UPDATES

Stage III NSCLC: Overview

TRANSPORTATION RESEARCH BOARD. TRB 98th Annual Meeting January 13-17, 2019 How to Survive and Thrive. Title goes here

ACOSOG Thoracic Committee. Kemp H. Kernstine, MD PhD

Tarceva. Tarceva (erlotinib) Description

Young Investigator Initiative for the Conduct of ACRIN Ancillary Research

Credentialing for the Use of IGRT in Clinical Trials

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD

CancerPACT Cancer Patients Alliance for Clinical Trials

Two Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens

trial update clinical

Transcription:

Volume 2: ISSUE 7: April 7, 2010 The Clinical Research E-News SPECIAL ALERT: The annual JOG investigator Meeting will be held at 5pm on May 10, 2010 at the Loews Hotel. Now Open: RTOG0831, A Randomized, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate the Effectiveness of a Phosphodiesterase 5 Inhibitor, Tadalafil, in Prevention of Erectile Dysfunction in Patients Treated with Radiotherapy for Prostate Cancer. GOG 258, A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma Coming soon: NSABP FC-6, A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mfolfox7 Plus Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer with Metastases Confined to the Liver E2508, A Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients with (Bevacizumab-eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC) E3903, Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients Considered for ECOG Treatment Trials for Leukemia or Related Hematologic Disorders.

RTOG0627, Phase II Trial of Dasatinib in Patients with Recurrent Glioblastoma Multiforme, will be opened to the JKCCN only SWOG0521, A Randomized Trial of Maintenance Versus Observation for Patients with Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL), Phase III. ECOG 3805,CHAARTED - Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer CALGB 70604, A Randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer RTOG 0937, Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC) RTOG 0915, Randomized Phase II Study Comparing 2 Stereotactic Body Radiation Therapy (SBRT) Schedules for Medically Inoperable Patients with Stage I Peripheral Non-Small Cell Lung Cancer RTOG 0618, A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Operable Stage I/II Non-Small Cell Lung Cancer If your site is interested in participating in any of these studies please contact Rolma Gano at 215-955-7954 or Rolma.gano@jeffersonhospital.org. Regulatory Update: The following studies have had recent consent form changes or updated letters posted on the repository website:

JOG 49 PACCT-1 ECOG 4805 SWOG 0600 RTOG 0848 RTOG 0539 RTOG 0631 GOG258-New Activation RTOG0831- New Activation RTOG 0415 CALGB 90601 RTOG 0848 If any of these studies pertain to your site please visit the repository at: http://www.kimmelcancercenter.org/kcc/jkccn/file-repository/. Please contact Rolma Gano with any repository or other regulatory related questions. Quality Assurance Update: Please contact Kelly Shipman with any QA related issues at 215-955-2135 or Kelly.shipman@jeffersonhospital.org. CTSU Update: The following protocols are now available on the OPEN system: E1208. Please see the OPEN tab on the CTSU Members web site for more information about the protocols in OPEN. If you have a CTSU related question please contact Joshua Schoppe at 215-955-0048 or Joshua.schoppe@jeffersonhospital.org. ECOG Update: The ECOG Registration System will be unavailable on Wednesday April 7, between 4:30 PM and 5:30 PM Eastern time, so that CTSU can activate E1208 in the OPEN system. E2805: Addendum #9 will be released on April 28, 2010. This addendum contains changes to the adverse event section and risks section of the consent for both Sorafenib and Sunitinib. This addendum will be submitted to the

TJUH IRB and it will be at their discretion to mandate a re-consent of all patients on study. Once this addendum is approved by the TJUH IRB we will notify all sites on how to proceed for all current E2805 patients. ECOG Spring Meeting: The ECOG spring meeting will be held at the JW Marriott Hotel in Washington, D.C., June 11 th through the 13 th. Meeting registration will be done online again for this meeting. To register for the Group Meeting, please use the link below. Please note that the schedule is updated on an ongoing basis. The schedule provided is for current reference only and is subject to change at any time. ECOG strongly recommends that all meeting attendees check the most current schedule online before making travel arrangements, as ECOG will not be responsible for ticket change fees due to scheduling changes. https://www.regonline.com/ecog_spring2010 If you have an ECOG related question please contact Joshua Schoppe. NSABP Update: NSABP Group Meeting: Registration is now open for the NSABP Group Meeting in San Francisco scheduled for April 22-25. The registration link below is not posted on the NSABP website. http://www.meetingsinfo.com/hotelinformation/san_francisco/home.html Registration deadline has passed but it may still be possible to register. A tentative meeting schedule has been posted on the registration website. NSABP audit: Please mark your calendar for the NSABP audit scheduled for June 21, 2010. The chart of any JKCCN NSABP patient accrued in the last 3 years may be selected for audit. We will be notified of the announced charts on May 24, 2010.

If you have an NSABP related question please contact Vicki Squire at vicki.squire@kimmelcancercenter.org or at 215-503-5641. RTOG Update: The next RTOG Semiannual meeting will be held June 17-20, 2010, at the Loews Philadelphia Hotel in Philadelphia, PA. General information about the meeting can be found at http://rtog.org/meeting/main.html. Please preregister via the following link: https://registrations.acr.org/rtog/. The March issues of the RTOG 0436, RTOG 0539, and RTOG 0617 newsletters were just issued and can be found at the following locations: http://rtog.org/members/protocols/0436/0436broadcast.html http://rtog.org/members/protocols/0539/0539newsletters/0539%20march%20 Newsletter.pdf http://rtog.org/members/protocols/0617/0617broadcast.html If you have an RTOG related question please contact Kelly Shipman. Jefferson Oncology Group (JOG) Update: If your site has any JOG inquires please contact either Josh Schoppe or Vicki Squire. Jefferson Kimmel Cancer Center Network Homepage: http://www.kimmelcancercenter.org/jkccn/. This page contains links to the Remote Access Portal as well as the clinical trial document repository. Upcoming Events: Oral Cancer Screening Event, TJU: April 14, 2010 NSABP Group Meeting, San Francisco: April 22-25 JOG Investigator Meeting, Philadelphia: May 10 ECOG Spring Meeting, Washington, D.C.: June 11-13

RTOG Semiannual Meeting, Philadelphia, PA: June 17-20 The Clinical Research E-News Archive is now located on the Kimmel Cancer Center webpage under the JKCCN Member Area: http://www.kimmelcancercenter.org/jkccn/e-newsletters.html Please provide feedback and any suggestions to Joshua Schoppe at 215-955- 0448 or email Joshua.schoppe@jeffersonhospital.org